Abstract

In this issue of EMBO Molecular Medicine, Stebbing etal (2020b) validate an artificial intelligence-assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID-19. Using liver organoids infected with SARS-CoV-2, they confirm dual antiviral and anti-inflammatory activities and show thatits administration in four COVID-19 patients is correlated with disease improvement, paving the way for more rigorous placebo-controlled trials.

Highlights

  • In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) validate an artificial intelligence-assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID-19

  • S evere COVID-19 cases are associated with hyperactivation of the immune system, which can lead to acute respiratory distress syndrome, other secondary immune disorders, and death (Mehta et al, 2020)

  • A drug that combines antiviral and immunosuppressant activities could be a powerful treatment (Perricone et al, 2020). In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) test the prediction that an anti-inflammatory molecule used for rheumatoid arthritis (RA) has antiviral activity and could improve the outcomes of those afflicted by severe COVID-19 (Fig 1)

Read more

Summary

Introduction

In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) validate an artificial intelligence-assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID-19. A drug that combines antiviral and immunosuppressant activities could be a powerful treatment (Perricone et al, 2020). In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) test the prediction that an anti-inflammatory molecule used for rheumatoid arthritis (RA) has antiviral activity and could improve the outcomes of those afflicted by severe COVID-19 (Fig 1).

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.